Inactivation of SARS-CoV-2 Laboratory Specimens

View More View Less
  • 1 Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana;
  • 2 Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana

The burden on diagnostic and research laboratories to provide reliable inactivation for biological specimens to allow for safe downstream processing is high during the coronavirus disease 2019 (COVID-19) pandemic. We provide safety data regarding commonly used chemical and physical inactivation procedures that verify their effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Author Notes

Address correspondence to Heinz Feldmann, Rocky Mountain Laboratories, 903 South 4th Street, Hamilton, MT 59840. E-mail: feldmannh@niaid.nih.gov

Financial support: Funding for this study was provided by the Intramural Research Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Authors’ addresses: Elaine Haddock, W. Lesley Shupert, and Heinz Feldmann, Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, E-mails: elaine.haddock@nih.gov, wlshupert@niaid.nih.gov, and feldmannh@niaid.nih.gov. Friederike Feldmann, Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, E-mail: feldmannfe@niaid.nih.gov.

Save